A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer-Reference-Cited by-同舟云学术

A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer

Published:2017-12 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Kollmorgen Gwendlyn,Palme Klara,Seidl Annette,Scheiblich Stefan,Birzele Fabian,Wilson Sabine,Clemens Christian,Voss Edgar,Kaufmann Martin,Hirzel Klaus,Rieder Natascha,Krippendorff Ben-Fillippo,Herting Frank,Niederfellner Gerhard

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-017-17329-7.pdf

Reference42 articles.

1. Weldon, J. E. & Pastan, I. A guide to taming a toxin–recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J. 278, 4683–4700 (2011).

2. Dosio, F., Stella, B., Cerioni, S., Gastaldi, D. & Arpicco, S. Advances in anticancer antibody-drug conjugates and immunotoxins. Recent Pat Anticancer Drug Discov. 9, 35–65 (2014).

3. Hassan, R. et al. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer 120, 3311–3319 (2014).

4. Bauss, F. et al. Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy. Mol. Oncol. 10, 1317–1329 (2016).

5. Weldon, J. E. et al. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol. Cancer Ther. 12, 48–57 (2013).

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The challenge of selecting tumor antigens for chimeric antigen receptor T-cell therapy in ovarian cancer;Medical Oncology;2022-09-29

2. Comparison of CD3e Antibody and CD3e-sZAP Immunotoxin Treatment in Mice Identifies sZAP as the Main Driver of Vascular Leakage;Biomedicines;2022-05-24

3. Pseudomonas Exotoxin-Based Immunotoxins: Over Three Decades of Efforts on Targeting Cancer Cells With the Toxin;Frontiers in Oncology;2021-12-16

4. Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors;Biomolecules;2020-06-28

5. IgY-technology (egg yolk antibodies) in human medicine: A review of patents and clinical trials;International Immunopharmacology;2020-04